A Phase II Clinical Study of SHR-1826 for Injection in Patients With NSCLC

Sponsor
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Study ID
NCT06844474
Phase
PHASE2
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - 75 Years
Healthy Volunteers
Not accepted

Interventions

  • SHR-1826；Adebrelimab；SHR-8068；Bevacizumab — DRUG
    Drug: Drug: SHR-1826 Administration by intravenous infusion for a cycle of 3 weeks. Drug: Adebrelimab Administration by intravenous infusion for a cycle of 3 weeks. Drug: SHR-8068 Administration by intravenous infusion for a cycle of 6 weeks. Drug: Bevacizumab Administration by intravenous infusion for a cycle of 3 weeks.

Study Details

This study is an open-label, multicenter Phase II clinical trial to evaluate the safety, tolerability and efficacy of SHR-1826 for injection in patients with NSCLC.

Key Dates

First listed
Feb 25, 2025
Start date
Mar 7, 2025
Status verified
Feb 2025
Primary completion
Aug 31, 2026
Completion
Feb 29, 2028

Study Design

Enrollment
300 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Arm A
    SHR-1826 for injection in combination with Adebrelimab injection and SHR-8068 with or without Bevacizumab injection

Primary Outcome Measure

Incidence and severity of adverse events (AEs) /serious adverse events(SAEs) [ Time Frame: approximately 2 years ]

Central Contacts

Related Studies